ERBB2 and diabetes mellitus: The fact that acute or chronic treatment with AG825, a specific inhibitor of ErbB2 phosphorylation, led to normalization of the altered vasoconstrictor and vasodilator responses in the diabetic mesenteric vascular bed (Figure 1) implied that ErbB2 signaling was an important contributing pathway in the development of vascular dysfunction associated with diabetes.